The pathophysiology of hypertrophic cardiomyopa- The last ESC Guidelines on HF specified that "no treatment has yet been shown, convincingly, to reduce morbidity or mortality in patients with
HFpEF." This is due to the fact that the physiopathology of this disease is still misunderstood, but also because we lack quantitative and reproductive tools to evaluate heart failure with preserved ejection fraction, specifically for HCM. We believe that the MS estimated by SWI may be an interesting predictor of outcome and may help to stratify patients for the evaluation of treatment strategies. In addition, it might be interesting to evaluate the effect of drugs currently used in HCM on MS values. If any positive effect is seen in association with changes in outcomes, MS could be used as a surrogate or as a therapeutic target in future trials.
In this study, we quantitatively assessed the diastolic MS in children using SWI in healthy volunteers and pediatric HCM. MS was high in children with HCM and even higher in those with a restrictive physiology. In addition, the fractional anisotropy obtained by SWI could help provide additional information on the myocardial structure.
Our study remains descriptive, but it offers the perspective to evaluate this new noninvasive marker as a potential predictor of outcome and as a potential therapeutic target. 
